Ultimovacs' Phase II FOCUS Trial of UV1 in Head and Neck Cancer Fails to Meet Endpoints
核心洞察
The Phase II FOCUS trial evaluating Ultimovacs (搜索)' UV1 vaccine in combination with pembrolizumab for head and neck squamous cell carcinoma (搜索) (HNSCC) did not meet its primary endpoint of improved progression-free survival.
Secondary endpoints, including overall survival, were also not met in the study, which investigated UV1 plus pembrolizumab versus pembrolizumab alone.
UV1 demonstrated a positive safety profile, consistent with previous studies, with similar adverse events observed in both the treatment and control arms.
The Phase II FOCUS trial, investigating Ultimovacs (搜索)' UV1 cancer vaccine in combination with pembrolizumab for the treatment of head and neck squamous cell carcinoma (搜索) (HNSCC), has failed to meet its primary and secondary endpoints. The study, an investigator-sponsored, randomized, open-label trial, aimed to assess the clinical performance of UV1 vaccination when added to standard pembrolizumab treatment in patients with metastatic or recurrent PD-L1 positive HNSCC.
The trial, sponsored by the Medical Faculty, University of Halle-Wittenberg in Germany, randomized 75 patients to receive either UV1 plus pembrolizumab (50 patients) or pembrolizumab alone (25 patients). The primary endpoint was progression-free survival (PFS) rate at 6 months. Secondary endpoints included overall survival (OS), objective response rate (ORR), duration of response (DOR), and safety.
Lack of Clinical Benefit
Topline data indicated that the addition of UV1 to pembrolizumab did not result in clinical benefits in progression-free survival or overall survival. UV1 continued to demonstrate a positive safety profile in line with other UV1 studies with similar events observed in the control arm and good tolerability.
About UV1
UV1 is a universal cancer vaccine designed to induce a specific T cell response against telomerase (搜索). The vaccine consists of long, synthetic peptides representing a sequence in the reverse transcriptase subunit of telomerase (hTERT), which has been shown to induce CD4+ T cells. These CD4+ T cells have the potential to provide inflammatory signals and T cell support that are believed to be critical for triggering a strong anti-tumor immune response.
FOCUS Trial Design
The FOCUS trial enrolled its first patient in August 2021, treating patients across 10 sites in Germany. The trial investigated the tolerability and efficacy of adding UV1 to standard of care treatment with programmed death receptor-1 (PD-1)-blocking antibody pembrolizumab versus pembrolizumab monotherapy. The primary endpoint was PFS rate at 6 months after first administration of study medication. Secondary endpoints included PFS and OS (overall survival, by Kaplan-Meier estimate), objective response rate (ORR), duration of response (DOR) and safety, with minimum 12 months follow-up.